Cencora Inc. ($COR) Stock Forecast: Down 5.0% Today

What is Cencora Inc.?

Cencora Inc (NYSE: COR) announced the retirement of its CFO, James F. Cleary, effective June 30, 2026. The company also reaffirmed its fiscal year 2026 guidance, demonstrating confidence in its business momentum and financial health.

Why is Cencora Inc. going down?

COR stock is down 5.0% on Mar 17, 2026 16:35

• The CFO's retirement at Cencora Inc may have triggered uncertainty among investors, resulting in a bearish movement in the stock.
• Despite the retirement news, the company's decision to uphold its fiscal year 2026 guidance suggests stability and confidence in its future performance.
• Investor caution during the transition period and the search for a successor may be contributing to the stock's downward pressure.
• Market sentiment towards Cencora Inc appears mixed, weighing the company's financial health and growth prospects against the CFO transition uncertainty.

COR Price Chart

COR Technical Analysis

COR News

Evercore ISI maintains Cencora stock rating on CFO transition

Evercore ISI has maintained its Outperform rating and a $420.00 price target for Cencora Inc (NYSE:COR) despite the announcement of CFO James Cleary's retirement. The firm views Cleary's continued involvement during the transition period positively, noting his contributions to financial discipline and growth. Cencora also reaffirmed its fiscal year 2026 guidance, signaling confidence in its business momentum and financial health.

https://m.investing.com/news/analyst-ratings/evercore-isi-maintains-cencora-stock-rating-on-cfo-transition-93CH-4566010?ampMode=1

Cencora, Inc. Announces Retirement of James F. Cleary as Executive Vice President, Effective June 30, 2026

Cencora, Inc. has announced the retirement of James F. Cleary as Executive Vice President, effective June 30, 2026. Mr. Cleary, who is 62, joined the company in February 2015 after its acquisition of MWI Veterinary Supply, where he served as CEO for over a decade and as CFO of Cencora since November 2018. He will assist in the search for his successor and serve in an advisory capacity through the end of 2026 to ensure a smooth transition.

https://www.marketscreener.com/news/cencora-inc-announces-retirement-of-james-f-cleary-as-executive-vice-president-effective-june-30-ce7e5edbd18ef325

Cencora CFO James F. Cleary To Retire

Cencora, Inc. (NYSE: COR) announced that Executive Vice President and CFO James F. Cleary will retire effective June 30, 2026. Cleary, who has served as CFO since November 2018, will assist in the search for a successor and serve in an advisory capacity through the end of 2026 to ensure a smooth transition. The company also reaffirmed its adjusted diluted EPS guidance for fiscal year 2026.

https://www.citybiz.co/article/819595/cencora-cfo-james-f-cleary-to-retire/

Cencora CFO Retirement Announced, Financial Guidance Reaffirmed

Cencora (COR), a global pharmaceutical solutions provider, announced the retirement of its CFO, James F. Cleary, effective June 30, 2026. Despite this leadership change, the company reaffirmed its adjusted diluted earnings per share guidance for fiscal 2026, ranging from $17.45 to $17.75. TipRanks' AI Analyst, Spark, rated COR as Neutral, noting strong cash generation and a constructive earnings outlook, tempered by balance-sheet leverage and modest dividend yield.

https://www.tipranks.com/news/company-announcements/cencora-cfo-retirement-announced-financial-guidance-reaffirmed

Oil Surged 33% in a Week: 3 Commodity ETFs to Buy as the Hormuz Crisis Deepens

The closure of the Strait of Hormuz by Iran and escalating drone strikes in the Middle East have significantly impacted global oil supply, causing WTI crude prices to surge by 33% in a week. This article recommends three commodity ETFs—United States Oil Fund (USO), United States Brent Oil Fund (BNO), and Invesco DB Oil Fund (DBO)—as investment options to capitalize on the rising oil prices. Each ETF offers different approaches to oil price exposure, with varying expense ratios, asset sizes, and strategies for managing futures contracts.

https://247wallst.com/investing/2026/03/17/oil-surged-33-in-a-week-3-commodity-etfs-to-buy-as-the-hormuz-crisis-deepens/

Trending Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 9.3% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 5.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.4% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 5.7% Today

Kimco Realty Corporation ($KIM) Stock Forecast: Down 3.5% Today

SL Green Realty Corp ($SLG) Stock Forecast: Down 5.2% Today

StoneCo Ltd. ($STNE) Stock Forecast: Down 5.2% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 5.0% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Down 5.4% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.2% Today

Cencora Inc. Price History

05.01.2026 - COR Stock was up 7.6%

• The surge in Cardinal Health's stock price followed strong fiscal second-quarter earnings that exceeded analyst expectations, demonstrating solid financial performance and surpassing revenue projections.
• Investor optimism and the subsequent bullish market movement were fueled by the company's strategic emphasis on specialty drugs and pharmaceutical solutions, along with an upward revision of earnings guidance.
• Cardinal Health's favorable prospects are bolstered by the growing demand for high-margin specialty medications across the industry, in line with the company's growth strategy and financial achievements.

06.00.2026 - COR Stock was up 5.1%

• The bullish movement in Cencora's stock today can be attributed to the strong fiscal second-quarter results from a key player in the pharmaceutical distribution industry.
• Impressive earnings momentum from specialty and automation services in the sector has likely boosted investor confidence industry-wide, including companies like Cencora.
• Concerns raised about Cencora's valuation and lowered price target have been overshadowed by the overall positive outlook for the company, particularly with its recent acquisition and growth targets.
• The increasing interest from institutional investors and hedge funds in Cencora, as noted in the ownership structure, indicates growing confidence in the company's future prospects, contributing to the bullish trend observed today.

05.00.2026 - COR Stock was down 0.6%

• A notable adjustment was made to COR's price target by B of A Securities, lowering it from $380.00 to $360.00. This change, amidst other analysts raising their targets, may have contributed to the bearish movement.
• Institutional confidence in COR was highlighted when Gateway Investment Advisers LLC significantly increased its stake in the company by 1,135.4% to $37.23 million. However, recent insider selling activities may have raised concerns among investors.
• Comments on COR's strong fundamentals, resilient earnings, and strategic focus on specialty distribution and biosimilars have surfaced, suggesting a positive outlook. This implies that the bearish movement could be a temporary correction rather than an indicator of the company's long-term potential.
• The market movements observed today regarding COR could be explained by short-term price adjustments resulting from conflicting analyst opinions and profit-taking behaviors following a period of consistent value appreciation.

05.01.2026 - COR Stock was up 6.9%

• COR's bullish movement can be attributed to the company's strategic focus on specialty pharmaceuticals and recent acquisitions like OneOncology, which are seen as key drivers for future growth.
• The market reacted positively to COR beating adjusted EPS expectations, despite missing revenue estimates, showcasing investor confidence in the company's growth strategy.
• The overall positive sentiment towards specialty pharmaceuticals, as seen with another company's strong performance and profit forecast boost, likely contributed to the bullish movement in COR's stock.
• COR's emphasis on segment leadership in specialty pharmaceuticals amidst market competition and financing challenges indicates a promising outlook, driving investor optimism and pushing the stock higher.

05.10.2025 - COR Stock was down 0.1%

• Despite Cencora (COR) surpassing earnings and revenue estimates for Q4, the stock exhibited bearish movement.
• Investors may have had higher expectations or anticipated growth projections beyond the reported numbers, resulting in a sell-off.
• Market sentiment could have been swayed by external factors such as macroeconomic uncertainties or industry shifts, rather than the company's financial achievements.
• Some investors might have opted to take profits after the positive news, leading to a temporary decline in the stock price.

04.01.2026 - COR Stock was down 8.7%

• Despite surpassing EPS expectations, Cencora (COR) faced a bearish market response due to slightly missing revenue estimates in Q1.
• The stock price declined as the revenue fell short at $85.9 billion, compared to the consensus estimate of $86.02 billion.
• The company's strong position in the U.S. pharmaceutical wholesale market and the successful OneOncology acquisition could have positive long-term effects. However, short-term market sentiment was impacted by the revenue shortfall.
• Concerns about the company's valuation metrics potentially indicating overvaluation may have contributed to the bearish movement, despite the positive surprise in EPS.

04.01.2026 - COR Stock was down 6.3%

• Despite exceeding EPS expectations in Q1, Cencora's stock faced a downward trend, possibly influenced by revenue falling beneath estimates.
• The completion of the OneOncology acquisition and the increased guidance for fiscal 2026 operating income growth were favorable developments for the company.
• The market's negative response to the revenue miss suggests investor focus on top-line performance.
• Concerns about the stock's overvaluation and a slight revenue shortfall in contrast to estimates likely played a role in today's bearish movement.

04.01.2026 - COR Stock was down 9.2%

• Cencora (COR) posted remarkable first fiscal quarter earnings, outperforming expectations on adjusted EPS and displaying revenue growth compared to the previous year.
• The stock's decline might be linked to a slight shortfall in revenue compared to Wall Street estimates, despite the positive earnings results.
• The completion of the OneOncology acquisition and the revised guidance for fiscal 2026 signal favorable growth prospects for Cencora, but concerns regarding overvaluation could have influenced the market's reaction.
• Overall, the market's bearish response may stem from a combination of revenue missing estimates, worries about overvaluation, and profit-taking after the stock's recent performance.

16.11.2025 - COR Stock was down 2.4%

• Factors contributing to the bearish movement in Cencora's stock (COR) today include:
• Concerns over the significant financial commitment of $5 billion for the OneOncology acquisition, impacting immediate financials.
• Investor caution regarding the initial EPS neutrality and timeline for positive contribution from the deal by mid-fiscal year 2027, despite positive analyst sentiment and raised price targets post-acquisition.
• Influence of recent market fluctuations and economic data on broader market sentiment, potentially affecting COR stock movement.
• Investor hesitancy as they wait to see the ultimate impact of OneOncology acquisition on Cencora's market position and financial performance, resulting in a temporary decline in stock price.

17.02.2026 - COR Stock was down 5.0%

• The CFO's retirement at Cencora Inc may have triggered uncertainty among investors, resulting in a bearish movement in the stock.
• Despite the retirement news, the company's decision to uphold its fiscal year 2026 guidance suggests stability and confidence in its future performance.
• Investor caution during the transition period and the search for a successor may be contributing to the stock's downward pressure.
• Market sentiment towards Cencora Inc appears mixed, weighing the company's financial health and growth prospects against the CFO transition uncertainty.

17.02.2026 - COR Stock was down 5.0%

• The retirement announcement of the Chief Financial Officer may have caused uncertainty among investors, leading to a bearish movement in the stock.
• The significant reduction in stock holdings by multiple management entities and insiders selling shares worth millions could have signaled a lack of confidence in the company's future performance.
• Despite holding steady amid healthcare distribution resilience and positive market outlook, the downward revision in stock evaluation and increased selling activities might have contributed to the bearish trend in COR's stock price.
• The combination of insider selling, reduction in institutional stakes, and mixed market indicators could have created a negative sentiment around COR, leading to the bearish movement observed today.

12.01.2026 - COR Stock was down 2.4%

• Several factors may explain the bearish movement in COR's stock price today:
• The reduction in stake by Atria Investments Inc following positive earnings and dividend news may have raised concerns about the company's future growth prospects.
• The issuance of $3 billion in senior unsecured notes could have led to worries about increased debt levels and potential shareholder value dilution.
• Market sentiment toward healthcare companies, exemplified by Cosmos Health's pivot to Bitcoin, may have negatively impacted COR's stock price.
• The forthcoming ex-dividend date for COR may have prompted some investors to liquidate their holdings, contributing to the stock's bearish trend.